VBI Vaccines announces second positive DSMB review in phase 1/2a study of VBI-1901
VBI Vaccines announced the independent DSMB completed its second safety assessment of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent GBM. The DSMB reviewed the complete safety data and unanimously recommended the continuation of the study without modification.
September 25, 2018